Monoclonal antibody (mAb) therapy can be used for both treatment and post-exposure prophylasix for COVID-19. This therapy provides immediate, short-term immunity and has shown to reduce hospitalization and death rates by 70% among high risk COVID-19 patients. It is currently administered by infusion only and an injectable form is under development.

Candidates for mAb include:

• Treatment
  • COVID19 + and
  • 12 years of age or older (weighs ≥ 40 kg) and
  • Symptomatic for less than 10 days and
  • Has a high-risk medical condition or is 65 years of age or older
• Post Exposure Prophylaxis
  • Non-vaccinated person with a high-risk medical condition and
  • Close exposure* to someone with COVID-19 
• Post Exposure Prophylaxis
  • Vaccinated person with a high-risk medical condition and
  • Close exposure* and may not have completed the vaccine series or may not have fully responded to the vaccine

*close exposure is defined by the CDC as within 6 feet of an infected person for 15 minutes or more over a 24-hour period without masking

Treatment is safe and effective for people who have been previously immunized or infected with COVID-19. Patients receiving mAb should receive the COVID vaccine or booster within 90 days of infusion.